Prostanoid Receptor EP2 as a Therapeutic Target

• Authors: Thota Ganesh, Emory University
• Journal Title: Journal of Medicinal Chemistry
• Volume: Volume 57, Number 11
• Publisher: American Chemical Society | 2014-06-12, Pages 4454-4465
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1021/jm401431x
• Subjects: Health Sciences, Pharmacology
• Keywords: Science & Technology; Life Sciences & Biomedicine; Chemistry, Medicinal; Pharmacology & Pharmacy; INFLAMMATORY-BOWEL-DISEASE; OPEN-ANGLE GLAUCOMA; PROSTAGLANDIN E-2; MICROGLIAL ACTIVATION; SELECTIVE-INHIBITION; OXIDATIVE DAMAGE; CLINICAL-TRIAL; MICE LACKING; IN-VITRO; AGONIST

Abstract

Cycoloxygenase-2 (COX-2) induction is prevalent in a variety of (brain and peripheral) injury models where COX-2 levels correlate with disease progression. Thus, COX-2 has been widely explored for anti-inflammatory therapy with COX-2 inhibitors, which proved to be effective in reducing the pain and inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit to patients with chronic inflammatory neurodegenerative disease. Recently, two COX-2 drugs, rofecoxib and valdecoxib, were withdrawn from the United States market due to cardiovascular side effects. Thus, future anti-inflammatory therapy could be targeted through a specific prostanoid receptor downstream of COX-2. The PGE2 receptor EP2 is emerging as a pro-inflammatory target in a variety of CNS and peripheral diseases. Here we highlight the latest developments on the role of EP2 in diseases, mechanism of activation, and small molecule discovery targeted either to enhance or to block the function of this receptor.